Glenmark Pharmaceuticals’ US arm recalls around 14.76 lakh bottles of Atomoxetine Capsules

03 Mar 2025 Evaluate

Glenmark Pharmaceuticals’ US-based subsidiary -- Glenmark Pharmaceuticals Inc, USA is recalling around 14.76 lakh bottles of Atomoxetine Capsules in multiple strengths. The company is recalling the affected lot due to ‘CGMP Deviations’. The recall is due to presence of N-Nitroso Atomoxetine impurity above the FDA recommended limit. 

New Jersey-based Glenmark Pharmaceuticals Inc, USA is recalling the made-in-India product in strengths ranging from 10 mg to 100 mg. 

The company initiated the Class II recall on January 29 this year. As per the USFDA, a Class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. ADHD is a neurodevelopmental disorder that affects a person's ability to focus, control impulses, and regulate their activity levels. It is one of the most common mental disorders affecting children.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.

Glenmark Pharma Share Price

1943.35 9.10 (0.47%)
21-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1612.55
Dr. Reddys Lab 1155.50
Cipla 1369.55
Zydus Lifesciences 876.10
Lupin 2139.40
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×